And we are comparing in Brilacidin a drug that mos
Post# of 72447
(Total Views: 517)
Posted On: 02/27/2021 11:32:22 PM
And we are comparing in Brilacidin a drug that most longs expect to perform outrageously good in efficacy, safety, and cost when compared to Rems.... so why would any doctor prescribe Rems... instead of Brilacidin?
The value should be staggering as I expect the usage of Brilacidin will far exceed the current demand for Rems...
I still don't buy the BS of IPIX needing a BP for CV19. We sell directly to governments in heavy volume and let them distribute throughout their country. At the worst, we hire a worldwide logistical distribution company to handle it and pay them 5-15% of sales. There would be many such companies that would take that in a heartbeat. But then again, this is something for Leo to figure out and he may deem otherwise. Hope he really crunches the numbers to see if BP/NO BP is the route to take. There may also be other factors he is weighing which we don't have access to that may influence his decision.
Now as for most other indications (maybe all except for Oral Mucositis) IPIX would be needing a BP partner IMO but I expect a bidding war for the Brilacidin platform that will set a new standard for bio startup/BP relationship in regards to royalty rates.
If one remembers when Tiger Woods came up he got a nice initial deal with Nike but Tiger's Dad said that it was pocket change to what he would get the next go around - and his Dad was right. IPIX will be a paradigm shifter in this regard for pharmaceuticals IMO and what they get paid for the B platform will stun the financial world IMO.
Why should a BP mind paying out many, many billions when they will make an even greater amount by owning the licensing rights and they incurred no risks in it's development?
The value should be staggering as I expect the usage of Brilacidin will far exceed the current demand for Rems...
I still don't buy the BS of IPIX needing a BP for CV19. We sell directly to governments in heavy volume and let them distribute throughout their country. At the worst, we hire a worldwide logistical distribution company to handle it and pay them 5-15% of sales. There would be many such companies that would take that in a heartbeat. But then again, this is something for Leo to figure out and he may deem otherwise. Hope he really crunches the numbers to see if BP/NO BP is the route to take. There may also be other factors he is weighing which we don't have access to that may influence his decision.
Now as for most other indications (maybe all except for Oral Mucositis) IPIX would be needing a BP partner IMO but I expect a bidding war for the Brilacidin platform that will set a new standard for bio startup/BP relationship in regards to royalty rates.
If one remembers when Tiger Woods came up he got a nice initial deal with Nike but Tiger's Dad said that it was pocket change to what he would get the next go around - and his Dad was right. IPIX will be a paradigm shifter in this regard for pharmaceuticals IMO and what they get paid for the B platform will stun the financial world IMO.
Why should a BP mind paying out many, many billions when they will make an even greater amount by owning the licensing rights and they incurred no risks in it's development?
(12)
(0)